5 years ago

Redirecting T cells to hematological malignancies with bispecific antibodies.

Stephen Gottschalk, Mireya Paulina Velasquez, Challice L Bonifant
There is a need to improve outcomes for patients with recurrent and/or refractory hematological malignancies. Immunotherapy holds the promise to meet this need since it does not rely on the cytotoxic mechanism of conventional therapies. Among different forms of immunotherapy, redirecting T cells to hematological malignancies with bispecific antibodies (BsAbs) is an attractive strategy. BsAbs are an 'off-the-shelf' product that is easily scalable in contrast to adoptive T-cell therapies. Among these, the bispecific T-cell engager (BiTE) blinatumomab has emerged as the most successful BsAb to date. It consists of two single chain variable fragments (scFvs) specific for CD19 present on B-cell malignancies, and CD3 expressed on almost all T cells. Blinatumomab has shown potent anti-tumor activity as a single agent, particularly for acute lymphoblastic leukemia (ALL) resulting in its FDA approval. However, while successful in inducing remissions, these are normally short-lived with median response durations of less than one year. Nevertheless, the success of blinatumomab has reinvigorated the BsAb field, which is bustling with preclinical and clinical studies not only for B-cell derived lymphoblastic leukemia and lymphoma, but also for acute myeloid leukemia and multiple myeloma. Here we will review successes and challenges of T-cell targeted BsAbs for the immunotherapy of hematological malignancies with special focus on conducted clinical studies and strategies to improve their efficacy.

Publisher URL: http://doi.org/10.1182/blood-2017-06-741058

DOI: 10.1182/blood-2017-06-741058

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.